EMA Authorised: Rasagiline Viatris (previously Rasagiline Mylan) (rasagiline tartrate) — Viatris Limited

View source ↗

Summary

The EMA authorised Rasagiline Viatris (rasagiline tartrate) for Parkinson's disease, with Viatris Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rasagiline Viatris (rasagiline tartrate)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Viatris Limited. Decision date: 26/11/2025